ERBB2 and breast carcinoma: This systematic review highlights the clinical efficacy and safety of combining pertuzumab, trastuzumab, and docetaxel across different treatment settings for HER2-positive breast cancer, including neoadjuvant, adjuvant, and metastatic contexts.